BCDA Stock Overview
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BioCardia, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.38 |
| 52 Week High | US$2.92 |
| 52 Week Low | US$0.32 |
| Beta | 1.49 |
| 1 Month Change | -6.30% |
| 3 Month Change | -10.30% |
| 1 Year Change | -81.21% |
| 3 Year Change | -89.34% |
| 5 Year Change | -96.02% |
| Change since IPO | -97.21% |
Recent News & Updates
Recent updates
Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns
Oct 12
BioCardia stock rises on contract for delivery products for BlueRock's cell therapies
Aug 24Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?
Aug 24Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation
May 10We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully
Jan 06We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully
Sep 23Why I've Taken A Small Position In BioCardia
Jun 14Shareholders May Not Be So Generous With BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation And Here's Why
Jun 08Is BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth Plans?
May 20BioCardia issued U.S. patent for Helix Biotherapeutic Delivery system
Dec 30BioCardia slips 11% on launch of direct offering
Dec 16BioCardia says DSMB feedback on cell therapy data in heart failure study anticipated soon
Dec 14Shareholder Returns
| BCDA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.1% | 1.0% | 1.2% |
| 1Y | -81.2% | 0.7% | 24.9% |
Return vs Industry: BCDA underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: BCDA underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| BCDA volatility | |
|---|---|
| BCDA Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BCDA's share price has been volatile over the past 3 months.
Volatility Over Time: BCDA's weekly volatility has decreased from 28% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 18 | Peter Altman | www.biocardia.com |
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure.
BioCardia, Inc. Fundamentals Summary
| BCDA fundamental statistics | |
|---|---|
| Market cap | US$10.10m |
| Earnings (TTM) | -US$11.57m |
| Revenue (TTM) | US$477.00k |
21.4x
P/S Ratio-0.9x
P/E RatioIs BCDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCDA income statement (TTM) | |
|---|---|
| Revenue | US$477.00k |
| Cost of Revenue | US$7.73m |
| Gross Profit | -US$7.25m |
| Other Expenses | US$4.32m |
| Earnings | -US$11.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | -1,519.71% |
| Net Profit Margin | -2,425.79% |
| Debt/Equity Ratio | 0% |
How did BCDA perform over the long term?
See historical performance and comparison